¹⁸F-deoxyglucose PET: useful in the management of patients with stem cell transplantation for lymphoma?

References

• Elstrom R, Guan L, Baker G et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood101(10), 3875–3876 (2003).
   PubMed Web of Science ®Google Scholar
• Paes FM, Kalkanis DG, Sideras PA, Serafini AN. FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. Radiographics30(1), 269–291 (2010).
   PubMed Web of Science ®Google Scholar
• Schöder H, Noy A, Gönen M et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J. Clin. Oncol.23, 4643–4651 (2005).
   PubMed Web of Science ®Google Scholar
• Bruzzi JF, Macapinlac H, Tsimberidou AM et al. Detection of Richter’s transformation of chronic lymphocytic leukemia by PET/CT. J. Nucl. Med.47, 8 (2006).
   Google Scholar
• Noy A, Schoder H, Gonen M et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann. Oncol.20(3), 508–512 (2009).
   PubMed Web of Science ®Google Scholar
• Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood110(10), 3507–3516 (2007).
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol.25(5), 579–586 (2007).
   PubMed Web of Science ®Google Scholar
• Juweid ME, Stroobants S, Hoekstra OS et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J. Clin. Oncol.25(5), 571–578 (2007).
   PubMed Web of Science ®Google Scholar
• Delbeke D, Stroobants S, de Kerviler E, Gisselbrecht C, Meignan M, Conti PS. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. Oncologist14(Suppl. 2), 30–40 (2009).
   PubMed Web of Science ®Google Scholar
• Schöder H, Moskowitz C. PET imaging for response assessment in lymphoma: potential and limitations. Radiol. Clin. North Am.46(2), 225–241 (2008).
   PubMed Web of Science ®Google Scholar
• Robinson SP, Goldstone AH, Mackinnon S et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood100(13), 4310–4316 (2002).
   PubMed Web of Science ®Google Scholar
• Johnston PB, Wiseman GA, Micallef IN. Positron emission tomography using F18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin’s lymphoma. Bone Marrow Transplant.41(11), 919–925 (2008).
   PubMed Web of Science ®Google Scholar
• Schot BW, Zijlstra JM, Sluiter WJ et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood109(2), 486–491 (2007).
   PubMed Web of Science ®Google Scholar
• Poulou LS, Thanos L, Ziakas PD. Unifying the predictive value of pretransplant FDG PET in patients with lymphoma: a review and meta-analysis of published trials. Eur. J. Nucl. Med. Mol. Imaging37(1), 156–162 (2010).
   PubMed Web of Science ®Google Scholar
• Lambert JR, Bomanji JB, Peggs KS et al. Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. Blood115(14), 2763–2768 (2010).
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood102(1), 53–59 (2003).
   PubMed Web of Science ®Google Scholar
• Yoshimi A, Izutsu K, Takahashi M et al. Conventional allogeneic hematopoietic stem cell transplantation for lymphoma may overcome the poor prognosis associated with a positive FDG-PET scan before transplantation. Am. J. Hematol.83(6), 477–481 (2008).
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Vose J, Nademanee A, Gianni AM, Nagler A. Radioimmunotherapy for stem cell transplantation in non-Hodgkin’s lymphoma: in pursuit of a complete response. Oncologist14(Suppl. 2), 41–51 (2009).
   PubMed Web of Science ®Google Scholar
• Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood77 (3), 649–653 (1991).
   PubMed Web of Science ®Google Scholar
• Mandigers CM, Verdonck LF, Meijerink JP, Dekker AW, Schattenberg AV, Raemaekers JM. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant.32(12), 1159–1163 (2003).
   PubMed Web of Science ®Google Scholar
• Russell NH, Byrne JL, Faulkner RD, Gilyead M, Das-Gupta EP, Haynes AP. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant.36(5), 437–441 (2005).
   PubMed Web of Science ®Google Scholar
• Weiler-Sagie M, Bushelev O, Epelbaum R et al.18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J. Nucl. Med.51(1), 25–30 (2010).
   PubMed Web of Science ®Google Scholar
• Hart DP, Avivi I, Thomson KJ et al. Use of 18F-FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions. Br. J. Haematol.128(6), 824–829 (2005).
   PubMed Web of Science ®Google Scholar
• Mendler JH, Friedberg JW. Salvage therapy in Hodgkin’s lymphoma. Oncologist14(4), 425–432 (2009).
   PubMed Web of Science ®Google Scholar
• Bishop MR, Dean RM, Steinberg SM et al. Correlation of pretransplant and early posttransplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin’s lymphoma. Cancer116(4), 852–862 (2010).
   PubMed Web of Science ®Google Scholar